Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, et al. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat 2024 Aug 23. doi: 10.1007/s10549-024-07469.
PMID: 39177933